Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Adv ; 9(1): eade8898, 2023 01 06.
Artigo em Inglês | MEDLINE | ID: mdl-36608129

RESUMO

Atopic dermatitis (AD) is a chronic inflammatory skin condition increasing in industrial nations at a pace that suggests environmental drivers. We hypothesize that the dysbiosis associated with AD may signal microbial adaptations to modern pollutants. Having previously modeled the benefits of health-associated Roseomonas mucosa, we now show that R. mucosa fixes nitrogen in the production of protective glycerolipids and their ceramide by-products. Screening EPA databases against the clinical visit rates identified diisocyanates as the strongest predictor of AD. Diisocyanates disrupted the production of beneficial lipids and therapeutic modeling for isolates of R. mucosa as well as commensal Staphylococcus. Last, while topical R. mucosa failed to meet commercial end points in a placebo-controlled trial, the subgroup who completed the full protocol demonstrated sustained, clinically modest, but statistically significant clinical improvements that differed by study site diisocyanate levels. Therefore, diisocyanates show temporospatial and epidemiological association with AD while also inducing eczematous dysbiosis.


Assuntos
Dermatite Atópica , Humanos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/epidemiologia , Dermatite Atópica/diagnóstico , Disbiose/microbiologia , Isocianatos/uso terapêutico , Prevalência , Bactérias , Pele/microbiologia
2.
Eur J Pharmacol ; 906: 174263, 2021 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-34144027

RESUMO

Sigma-2 receptor/transmembrane protein 97 (TMEM97) is upregulated in cancer cells compared to normal cells. Traditional sigma-2 receptor agonists induce apoptosis and autophagy, making them of interest in cancer therapy. Recently, we reported a novel metabolically stimulative function of the sigma-2 receptor, showing increased 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and stimulation of glycolytic hallmarks. 6-Substituted analogs of the canonical sigma-2 receptor antagonist, 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), produce both metabolically stimulative and cytotoxic effects. Here, we compare the activities of two related compounds: 6-amino-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (CM571), the 6-amino derivative of SN79, which binds with high affinity to both sigma-1 and sigma-2 receptors, and 1,3-bis(3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)thiourea (MAM03055A), a homo-bivalent dimer of CM571. MAM03055A resulted from the degradation of 3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one (CM572), the cytotoxic 6-isothiocyanato SN79 derivative. MAM03055A exhibited high affinity and strong preference for sigma-2 receptors (sigma-1 Ki = 3371 nM; sigma-2 receptor Ki = 55.9 nM). Functionally, MAM03055A treatment potently induced cell death in SK-N-SH neuroblastoma, MDA-MB-231 breast, and both SW48 and SW480 colorectal cancer cell lines, causing proapoptotic BH3 interacting-domain death agonist (BID) cleavage in SK-N-SH cells. Conversely, CM571 induced metabolic stimulation. CM571 bound reversibly to both receptors, while MAM03055A bound pseudo-irreversibly to sigma-2 receptors and caused residual cytotoxic activity after acute exposure and removal of the compound from the media. Interestingly, MAM03055A induced a time-dependent loss of sigma-2 receptor/TMEM97 protein from cells, whereas monomer CM571 had no effect on receptor levels. These results suggest that monovalent and bivalent sigma-2 receptor ligands in this series interact differently with the receptor, thus resulting in divergent effects.


Assuntos
Antineoplásicos/farmacologia , Proteínas de Membrana/antagonistas & inibidores , Neoplasias/tratamento farmacológico , Receptores sigma/antagonistas & inibidores , Antineoplásicos/uso terapêutico , Benzoxazóis/farmacologia , Benzoxazóis/uso terapêutico , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Isocianatos/farmacologia , Isocianatos/uso terapêutico , Proteínas de Membrana/metabolismo , Neoplasias/patologia , Receptores sigma/metabolismo
3.
Neurol India ; 58(2): 259-63, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20508346

RESUMO

BACKGROUND: Distal anterior cerebral artery (DACA) aneurysms are less common, accounting for 3.1 to 9.2% of all intracranial aneurysms.The clinical characteristics and surgical techniques are quite different from those of other aneurysms of Willis circle. OBJECTIVE: We aimed to investigate the clinical and radiographic characteristics of ruptured distal anterior cerebral artery (DACA) aneurysms and the efficacy of endovascular treatment for these lesions. PATIENTS AND METHODS: From 1998 to 2008, 41 patients with 44 DACA aneurysms were treated by endovascular coiling, including parent vessel occlusion using coils or coils combined with n-butyle-2-cyanoacrylate (NBCA) in two, endosaccular coiling alone in 39, and stent-assisted coiling in three. RESULTS: Technical success was achieved in 40 (97.6%) patients. Among the 41 aneurysms successfully treated with endosaccular coiling or stent-assisted coiling, complete occlusion was obtained in 37, neck remnant in two, and partial occlusion in two. Two patients with poor pretreatment conditions died of cerebral vasospasm. The morbidity was 4.87%. One case each of unruptured recurrence and rebleeding were seen in follow-up DSA of 34 patients and MRA in five cases. CONCLUSION: Our preliminary results show that endovascular treatment for DACA aneurysms is safe and effective. However, the relative high recurrent rate highlights long-term follow-up for its security.


Assuntos
Aneurisma Roto/terapia , Embolização Terapêutica/métodos , Aneurisma Intracraniano/terapia , Stents , Adulto , Idoso , Angiografia Cerebral/métodos , Terapia Combinada , Feminino , Seguimentos , Humanos , Isocianatos/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença , Fatores de Tempo
4.
J Thromb Thrombolysis ; 13(1): 27-33, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11994557

RESUMO

BACKGROUND: Platelet deposition after angioplasty remains problematic and may contribute to intimal hyperplasia and restenosis. We proposed that polyethylene glycol diisocyanate (PEG-DISO), a polymer that rapidly forms covalent linkages with amine residues on proteins, could mask thrombogenic vascular wall proteins from platelets, thereby abrogating acute platelet deposition. METHODS AND RESULTS: To test this hypothesis, we isolated the femoral arteries of 10 New Zealand White rabbits and injured them with 3 passes of a 2F Fogarty catheter which was inserted through a distal arteriotomy. Immediately after balloon injury, (111)indium-labeled autologous platelets were infused peripherally and the injured femoral arteries were randomly treated for 1 minute with a PEG-DISO solution in one artery and a control solution of the phosphate buffered saline vehicle in the contralateral artery. Following treatment, reflow was initiated. The vessels were harvested after 1 hour and radioactivity was quantified in a gamma counter. Platelet counts were standardized by weight and expressed as platelets/mg (mean +/- SEM). Platelet deposition onto arteries treated with PEG-DISO was (1.2 +/- 0.5) x 10(6) platelets/mg compared to (5.6 +/- 4.2) x 10(6) platelets/mg onto the contralateral control arteries treated with vehicle (P < 0.005). Scanning electron micrographs of the injured vessel segment confirmed qualitatively less platelet deposition on the treated segments than on the control segments. CONCLUSION: Treatment with PEG-DISO significantly inhibited platelet deposition after vascular injury. These data support the hypothesis that treatment with PEG-DISO masks surface adhesive proteins from platelet receptors in vivo and that the resulting molecular barrier significantly reduces platelet deposition onto the damaged vessel wall for at least one hour. The formation of a molecularly thin barrier to platelet deposition may thus be a novel and effective treatment to abrogate acute intravascular thrombosis and may have value in the treatment of restenosis.


Assuntos
Angioplastia com Balão/efeitos adversos , Artéria Femoral/efeitos dos fármacos , Artéria Femoral/lesões , Isocianatos/farmacologia , Adesividade Plaquetária/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Polietilenoglicóis/farmacologia , Animais , Isocianatos/uso terapêutico , Polietilenoglicóis/uso terapêutico , Coelhos
5.
J Biomater Sci Polym Ed ; 10(11): 1159-70, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10606033

RESUMO

A series of segmented polyurethanes based on polyethylene oxide/polycaprolactone diol, isophorone diisocyanate, and dihydroxamic acids were synthesized and characterized. Biocompatibility and antitumoral activity were in vivo tested on Wistar male rats and Wistar rats affected with Walker 256 carcinosarcoma, respectively. The effect of dihydroxamic acid structure on the biological properties was determined. A better antitumoral response of the polyurethanes containing aliphatic dihydroxamic segment compared with those which resulted using terephthaloyl dihydroxamic acid was evidenced. With increasing polymer chain polyethylene oxide content the antitumoral activity was also enhanced. Some attempts on the in vitro biodegradation of above polyurethanes were also performed.


Assuntos
Antineoplásicos/química , Carcinoma 256 de Walker/tratamento farmacológico , Óxido de Etileno/química , Ácidos Hidroxâmicos/química , Isocianatos/química , Lactonas/química , Poliuretanos/química , Animais , Antineoplásicos/síntese química , Antineoplásicos/uso terapêutico , Biodegradação Ambiental , Ensaios de Seleção de Medicamentos Antitumorais , Óxido de Etileno/síntese química , Óxido de Etileno/uso terapêutico , Ácidos Hidroxâmicos/síntese química , Ácidos Hidroxâmicos/uso terapêutico , Isocianatos/síntese química , Isocianatos/uso terapêutico , Lactonas/síntese química , Lactonas/uso terapêutico , Masculino , Transplante de Neoplasias , Poliuretanos/síntese química , Poliuretanos/uso terapêutico , Ratos , Ratos Wistar
6.
J Med Chem ; 36(26): 4190-4, 1993 Dec 24.
Artigo em Inglês | MEDLINE | ID: mdl-8277500

RESUMO

2'-Deoxy-2'-isocyano-1-beta-D-arabinofuranosylcytosine (8, NCDAC) has been synthesized as a potential antitumor antimetabolite from a corresponding 2'-azido-2'-deoxy-1-beta-D-arabinofuranosyluracil derivative 2a. Uracil and thymine analogues 6a and 6b of 8 were also prepared. Attempts to synthesize 2'-deoxy-2'-isocyanocytidine (14b) failed due to the insertion of the 2'-alpha isocyano group into the 3'-OH group, affording the 2',3'-oxazoline derivative 15b. Stability of the isocyano derivative 6a and 2',3'-oxazoline derivative 15a under basic and acidic conditions were examined. The isocyano group in 6a was stable in basic conditions but unstable even in weakly acidic conditions to furnish the corresponding 2'-beta formamide derivative 17. Compound 15a was easily hydrolyzed the corresponding 2'-alpha formamide derivative 16 on treatment with H2O at room temperature. The cytotoxicity of 8, 6a, and 6b was examined in mouse and human tumor cells in vitro and compared with that of ara-C. Of these nucleosides, 8 was moderately cytotoxic to these cell lines. In vivo antitumor activity of 8 against Lewis lung carcinoma cells was also investigated and 8 showed only moderate tumor volume inhibition.


Assuntos
Antineoplásicos/síntese química , Desoxicitidina/análogos & derivados , Isocianatos/síntese química , Animais , Antineoplásicos/uso terapêutico , Citarabina/administração & dosagem , Citarabina/uso terapêutico , Desoxicitidina/administração & dosagem , Desoxicitidina/síntese química , Desoxicitidina/uso terapêutico , Estabilidade de Medicamentos , Humanos , Isocianatos/administração & dosagem , Isocianatos/uso terapêutico , Leucemia L1210/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Camundongos , Estrutura Molecular , Neoplasias Bucais/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Timina/análogos & derivados , Células Tumorais Cultivadas , Uracila/análogos & derivados
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...